Cover Image

Cessation or Continuation of Aspirin in Patients Undergoing 20-gauge Pars Plana Vitrectomy due to Diabetic Retinopathy

Reza Ajudani, Mohammad Hossein Khosravi, Mahdi Ramezani-Binabaj, Mohammad Saeid Rezaee-Zavareh, Ali agha Alishiri

Background: This study aimed to evaluate the incidence of ocular hemorrhages in patients with proliferative diabetic retinopathy (PDR) undergoing 20-gauge pars plana vitrectomy (PPV) taking aspirin as an antiplatelet agent versus those who did not take any aspirin. Materials and Methods: A total of 180 patients (mean age of 60.5 ± 9.9 years) with PDR referred to Baqiyatallah University Hospital in 2016 were enrolled in aspirin and control groups each group containing 90 patients. All participants underwent a standard 20-gauge diabetic PPV. Laboratory data, including fasting blood sugar, prothrombin time, partial thromboplastin, bleeding time, and platelets count, and intraoperative data, including bleeding and its type (retinal, subretinal, vitreous, conjunctival, sub-conjunctival, and hyphema), were collected and analyzed using SPSS16 software. Results: Bleeding occurred in 56 patients. There were no significant differences in the incidence of bleeding between aspirin (33 patients) and control groups (23patients) (P= 0.1). Likewise, no significant differences were observed in the type of bleeding between the two groups (P= 0.11). Age, gender, hypertension, type of operation, and laboratory findings were not significant between patients with and without bleeding. Conclusion: The results of this study indicated that taking aspirin is not associated with a higher risk of post-PPV surgery bleeding in comparison with the control group. Additionally, the type of bleeding did not significantly differ between the two groups. Hence, there is no urgent need for discontinuation of this medication in diabetic patients undergoing PPV.[GMJ.2017;6(2):95-101]

Aspirin; Diabetic Retinopathy; Eye Hemorrhage; Vitrectomy

Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 2004;27 Suppl 1:S72-3.

Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105(10):1801-15.

Albaladejo P, Samama CM. Patients under anti-platelet therapy. Best Pract Res Clin Anaesthesiol. 2010;24(1):41-50.

Charles S, Rosenfeld PJ, Gayer S. Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections. Retina. 2007;27(7):813-5.

West JF, Gregor ZJ. Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy. Br J Ophthalmol. 2000;84(8):822-5.

Yang CM. Surgical treatment for diabetic retinopathy: 5-year experience. J Formos Med Assoc. 1998;97(7):477-84.

Brown JS, Mahmoud TH. Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy. Retina. 2011;31(10):1983-7.

Fu AD, McDonald HR, Williams DF, Cantrill HL, Ryan EH, Jr., Johnson RN, et al. Anticoagulation with warfarin in vitreoretinal surgery. Retina. 2007;27(3):290-5.

Passemard M, Koehrer P, Juniot A, Bron AM

, Creuzot-Garcher C. Maintenance of anticoagulant and antiplatelet agents for patients undergoing peribulbar anesthesia and vitreoretinal surgery. Retina. 2012;32(9):1868-73.

Fabinyi DC, O'Neill EC, Connell PP, Clark JB. Vitreous cavity haemorrhage post-vitrectomy for diabetic eye disease: the effect of perioperative anticoagulation and antiplatelet agents. Clin Experiment Ophthalmol. 2011;39(9):878-84.

Lee BJ, Yu HG. Vitreous hemorrhage after the 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Retina. 2010;30(10):1671-7.

Park DH, Shin JP, Kim SY. Comparison of clinical outcomes between 23-gauge and 20-gauge vitrectomy in patients with proliferative diabetic retinopathy. Retina. 2010;30(10):1662-70.

Mason JO, 3rd, Gupta SR, Compton CJ, Frederick PA, Neimkin MG, Hill ML, et al. Comparison of hemorrhagic complications of warfarin and clopidogrel bisulfate in 25-gauge vitrectomy versus a control group. Ophthalmology. 2011;118(3):543-7.

Dayani PN, Grand MG. Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Arch Ophthalmol. 2006;124(11):1558-65.

Narendran N, Williamson TH. The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery. Acta Ophthalmol Scand. 2003;81(1):38-40.

Chauvaud D. [Anticoagulation and vitreoretinal surgery]. Bull Acad Natl Med. 2007;191(4-5):879-84.

Tan LT, Ziahosseini K, Cormack G, Charles S. Peri-operative Management of Antithrombotic Therapy in Vitreoretinal Surgery. 2009.

Chandra A, Jazayeri F, Williamson TH. Warfarin in vitreoretinal surgery: a case controlled series. Br J Ophthalmol. 2011;95(7):976-8.

Lip GY, Durrani OM, Roldan V, Lip PL, Marin F, Reuser TQ. Peri-operative management of ophthalmic patients taking antithrombotic therapy. Int J Clin Pract. 2011;65(3):361-71.

Oh J, Smiddy WE, Kim SS. Antiplatelet and anticoagulation therapy in vitreoretinal surgery. Am J Ophthalmol. 2011;151(6):934-9 e3.

Bonhomme F, Hafezi F, Boehlen F, Habre W. Management of antithrombotic therapies in patients scheduled for eye surgery. Eur J Anaesthesiol. 2013;30(8):449-54.

Donaldson LM, Donaldson MJ. Anticoagulation management in patients requiring small-gauge vitreoretinal surgery: a review of the literature. International Journal of Ophthalmic Practice. 2013;4(3):119-26.

Gallice M, Rouberol F, Albaladejo P, Brillat Zaratzian E, Palombi K, Aptel F, et al. [Managing antithrombotic therapy in vitreoretinal surgery.]. J Fr Ophtalmol. 2015;38(1):61-73.


  • There are currently no refbacks.